Bill CHIN, M.D,
Chief Medical Officer, Platform
Bill is the Chief Medical Officer, Platform of Frequency Therapeutics. He is formerly the Executive Vice President for Science and Regulatory Advocacy and Chief Medical Officer at the Pharmaceutical Research and Manufacturers of America (PhRMA) where he led PhRMA’s continuing efforts in science and regulatory advocacy in the drug discovery and development ecosystem. Prior to PhRMA, Bill was the Executive Dean for Research, Bertarelli Professor of Translational Medical Science and Professor of Medicine at Harvard Medical School (HMS) from 2010 to 2013. Before that, he was at Eli Lilly and Company last as Senior Vice President for Discovery Research and Clinical Investigation.
Bill is a Harvard-trained endocrinologist and longstanding faculty member. His career is exemplified in part by his extensive bibliography of nearly 300 papers, chapters and books, most of which were generated during his 25 years on the Harvard Medical School faculty. During this time, Bill was Chief of the Genetics Division in the Department of Medicine at Brigham and Women’s Hospital, a Howard Hughes Medical Institute investigator and Professor of Medicine at HMS. As a pioneering molecular endocrinologist at Harvard, Bill embraced the early use of emerging DNA technology to make important discoveries regarding the structure, function and regulation of hormone genes. His investigations often demonstrated a translational research theme, connecting basic laboratory discoveries to their physiologic relevance in animal models and humans. He has been honored with numerous awards for research, mentorship and leadership. Bill received his A.B. in Chemistry from Columbia University, and his M.D. from Harvard Medical School.